Scandinavian ChemoTech receives approval from the European Patent Office
Scandinavian ChemoTech AB announces today that the Company has received approval from the European Patent Office. The final injunction for this patent application was announced in a press release on the 3d of February 2021. The examiner announces that the approval will be published 7th of July 2021.
The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate.
This innovation provides improved pain control when using the Company's DEEPC™ (Dynamic Electro Enhanced Pain Control) device for IQwave™, for the delivery of electrical pulses to the desired body part.
“A few weeks ago, ChemoTech received CE marking for its medical technology product and system for cancer treatment. It is very gratifying to now also have this EU patent approved, which shows the wide technical range of ChemoTech’s TSE platform. We are now expanding the patent protection to also include pain relief, which is a very important part of cancer treatment. This approval gives ChemoTech's human and veterinary operations both the important protection needed for both the commercial establishment in the EU and that it attracts potential partners for distribution and / or licensing agreements. " - says Mohan Frick, CEO and author of this patent together with Prof B Persson
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.